[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chronic-respiratory-failure\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chronic-respiratory-failure":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,41,80,112,139,158,181,208,232],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":20,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":26,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100497372","improving-chronic-nocturnal-noninvasive-ventilation-a-multimodality-approach-100497372",false,"NCT05756387","Improving Chronic Nocturnal Noninvasive Ventilation: a Multimodality Approach","NOCTIVENT","Inclusion Criteria:\n\n* COPD patients indicated for chronic home NIV\n\nExclusion Criteria:\n\n* not able to read the written information and\u002For sign the informed consent form\n* no possibility to perfrom measurements at home","ALL",{"count":18,"type":19},100,"ESTIMATED","6 Months","OBSERVATIONAL","The aim of the data collection is to create an advanced reliable method to remotely monitor patient on chronic home non-invasive ventilation (NIV), both regarding ventilatory efficacy and patient comfort, both in the hospital and at home by assessing gas exchange, lung mechanics and the interaction between the patient and the ventilator.\n\nFor this purpose, we will set-up of databank of synchronously acquired datasets of already standard care monitored parameters during NIV (transcutaneous monitoring of gas exchange; ventilator data including data on PVA), and newly non-invasively acquired data on patient effort (EMG, patient ratings) and lung (hyper)inflation (EIT), during the set-up and follow-up of standard care chronic NIV.",[24,25],"Chronic Respiratory Failure","Non-invasive Ventilation",[27],"Monitoring","RECRUITING","2026-07-01",{"date":31,"type":32},"2026-07-02","ACTUAL",{"date":34,"type":32},"2024-12-01",{"date":36,"type":19},"2028-12-01",{"name":38,"class":39},"University Medical Center Groningen","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":65,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":79},"100598472","phase-2-a-clinical-trial-of-early-ventilation-in-amyotrophic-lateral-sclerosis-event-als-100598472","NCT07071935","A Clinical Trial of Early Ventilation in Amyotrophic Lateral Sclerosis (EVENT ALS)","A Pilot Randomized Clinical Trial of Early Ventilation in Amyotrophic Lateral Sclerosis (EVENT ALS)","EVENT ALS","Inclusion Criteria:\n\n* Diagnosed with ALS using the Gold Coast Criteria within the last 6 months\n* Age ≥18 years\n* Willingness and ability to participate in study procedures\n* Provision of signed and dated informed consent form\n\nExclusion Criteria:\n\n1. Current or prior or recommended\u002Fprescribed use of NIV including:\n\n   i) bi-level positive pressure ventilation, such as a respiratory assist device or home ventilator ii) Current or prior use of continuous positive airway pressure, or \"CPAP\" therapy\n2. Forced vital capacity \\\u003C50% of predicted normal\n3. Maximal inspiratory pressure \\> -60 cmH2O (eg, -50 or -40 cmH2O would be excluded)\n4. Chronic use of supplemental oxygen at any part of the day\n5. Enrollment in hospice\n6. Current tracheostomy\n7. Prior history of sleep apnea where non-invasive ventilation was used or recommended\n8. Thoracic, abdominal, facial or ophthalmic surgery in the prior 6 weeks\n9. Coughing up blood\n10. Myocardial infarction in the previous 4 weeks\n11. Absolute contraindication to NIV, which includes lethargy, obtundation, facial fractures, active pneumothorax, and airway obstruction (such as a tumor)\n12. Presence of cognitive dysfunction that would impair ability to complete study procedures, as determined by neurology attending physician","18 Years",{"count":51,"type":19},48,"INTERVENTIONAL",[54],"PHASE2","Amyotrophic lateral sclerosis (ALS) is a disease that causes weakness of the muscles of the body. The disease can eventually lead to severe breathing problems, which is the most common cause of death from ALS. The treatment for breathing is non-invasive ventilation (NIV). It is a machine that helps a person breathe by pushing air in and out of their lungs through a mask worn over the face. Research has shown that NIV can improve the quality of life and survival of someone with ALS. Unfortunately, NIV is not equally beneficial for everyone. The investigators do not yet know the best time or method for starting NIV in ALS. Europe and Canada allow starting NIV much earlier in ALS than the United States. Current recommendations for starting NIV are based on the opinion of experts rather than large research studies. Medical insurance companies will not cover NIV until significant breathing weakness occurs. After NIV is started, there is no evidence-based guidance on the best way to adjust NIV to benefit patients as much as possible. Some patients have difficulty tolerating NIV, but it is not clear how to identify these individuals ahead of time.\n\nThe investigators have created a new prediction tool that can identify patients at high risk of breathing problems within the next 6 months. This may help the study team identify who is more likely to benefit from starting NIV early. The investigators have published a paper that shows that NIV helps people with ALS live longer. This paper also showed that patients get more benefit with use NIV for at least 4 hours per day. The investigators published another paper that measured a gas called carbon dioxide (CO2), which goes high if someone's breathing is weakened. This paper showed that patients with ALS may live longer when CO2 levels are lowered using NIV. The investigators also have data suggesting that certain characteristics may predict who is less likely to use NIV at least 4 hours per day.\n\nIn this study, the investigators will collect pilot data on starting early NIV in individuals with ALS who do not yet meet insurance criteria for covering NIV. The research team will first use their previously published prediction tool to identify patient risk. Then, subjects would be randomized to start early NIV or to usual care. The usual care group would eventually start NIV as would occur if the participants were not in the study.\n\nThe purpose of this study is to collect data to help the investigators plan a larger randomized clinical trial. This study has 4 objectives. First, the project aims to identify individuals who would benefit from earlier NIV. The research team will use the original prediction tool to identify risk of severe breathing problems within the next 6 months. Second, the project aims to show that it is feasible to start NIV early. Third, the project aims to gather data on the effect of randomization on symptoms, CO2 levels, and outcomes. Fourth, the project aims to identify traits that may make someone less likely to use NIV.",[57,24,58,59,60,61,62,25,63,64],"Amyotrophic Lateral Sclerosis (ALS)","Neuromuscular Disease Patients","Neuromuscular Disease","Respiratory Insufficiency","Respiratory Insufficiency Requiring Mechanical Ventilation","Positive Pressure Ventilation","Non-invasive Ventilation Support","Non-invasive Ventilatory Support",[66,67,68,69],"chronic respiratory failure","chronic neuromuscular respiratory failure","non-invasive ventilation","amyotrophic lateral sclerosis","2026-06-25",{"date":72,"type":32},"2026-06-26",{"date":74,"type":32},"2026-06-11",{"date":76,"type":19},"2029-05",{"name":78,"class":39},"University of Pennsylvania",3,{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":4,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":4,"enrollmentInfo":87,"targetDuration":4,"studyType":52,"phases":89,"briefSummary":91,"conditions":92,"keywords":96,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":111},"100627695","effects-of-oxygen-supplementation-during-the-6-minute-walk-test-in-chronic-respiratory-failure-or-exertional-hypoxemia-100627695","NCT07451977","Effects of Oxygen Supplementation During the 6-Minute Walk Test in Chronic Respiratory Failure or Exertional Hypoxemia","Evaluation of the Effects of the Oxygen Supplementation During 6-minute Walking Test in Patients With Chronic Respiratory Failure or Exertional Hypoxiemia","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* Diagnosis of chronic respiratory disease admitted for pulmonary rehabilitation\n* One of the following conditions at discharge:\n* Chronic obstructive pulmonary disease with exertional hypoxemia\n* Chronic obstructive pulmonary disease with chronic respiratory failure requiring long-term oxygen therapy\n* Interstitial lung disease with chronic respiratory failure requiring long-term oxygen therapy\n* Clinically stable condition for at least one month\n* Optimized medical therapy during hospitalization\n* Ability to perform the 6-minute walk test\n* Signed informed consent\n\nExclusion Criteria:\n\n* Lung diseases other than chronic obstructive pulmonary disease or interstitial lung disease\n* Resting oxygen flow requirement greater than 4 liters per minute\n* Orthopedic, neurological, or cognitive conditions that may limit walking performance\n* Recent cardiovascular or cerebrovascular events within the previous 3 months",{"count":88,"type":19},114,[90],"NA","The aim of this multicenter crossover trial is to describe the effect of adding a therapeutic dose of exertional oxygen therapy, in terms of exercise performance, gas exchange, heart rate, symptoms perception and subjective easiness of performance, in a cohort of subjects hospitalized in specialized pulmonary rehabilitation centers with a diagnosis of chronic respiratory failure and\u002For exertional hypoxemia due to chronic obstructive pulmonary disease or interstitial lung disease.\n\nResearchers will compare the walking performance during 6-minute walk test performed with the liters of oxygen administered as prescribed at rest (for patients with chronic respiratory failure) or in room air (for patients with exertional hypoxemia only), to the performance during a 6-minute walk test performed with the double the flow rate prescribed at rest, or with 2 L\u002Fmin for patients with exertional hypoxemia only. The two tests will be performed in random order, at least 3 hours apart and no later than 24 hours apart from each other.\n\nThe main outcome will be the difference between the distance walked in the two 6-minute walk test in the two conditions. Furthermore, will be also collected and compared: the oxygen saturation and heart rate every minute, the initial and final dyspnea and fatigue, as assessed by Borg scale, and the easiness of performance through a dedicated questionnaire. The estimated sample size will be 114 patients.\n\nThis study will provide some basis for a more accurate prescription of exercise-related oxygen therapy, offering insights into the phenotype of patients who may derive the greatest benefit from this intervention. It will also stimulate discussion regarding the optimal timing and dosing of oxygen administration during exertion in patients with respiratory failure.",[24,93,94,95],"Hypoxemia","Chronic Obstructive Pulmonary Disease (COPD)","Interstitial Lung Disease",[97,98,66,99,100,101],"oxygen supplementation","6-minute walk test","exertional hypoxemia","pulmonary rehabilitation","exercise tolerance","2026-06-19",{"date":104,"type":32},"2026-06-23",{"date":106,"type":32},"2026-04-02",{"date":108,"type":19},"2028-09-30",{"name":110,"class":39},"Istituti Clinici Scientifici Maugeri SpA",6,{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":4,"eligibilityCriteria":118,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":4,"enrollmentInfo":119,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":121,"conditions":122,"keywords":123,"overallStatus":129,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":40},"100637998","validation-of-the-turkish-version-of-the-s3-niv-questionnaire-100637998","NCT07610122","Validation of the Turkish Version of the S3-NIV Questionnaire","Reliability and Validity of the Turkish Version of the Severe Respiratory Insufficiency Questionnaire for Non-Invasive Ventilation (S3-NIV)","Inclusion Criteria:\n\n* Diagnosed with chronic respiratory failure requiring home non-invasive ventilation (NIV).\n* Using a home NIV device for at least 3 months.\n* Being in a clinically stable phase (no exacerbation or hospitalization in the last 1 month).\n* Able to understand and answer the questionnaire.\n* Provided written informed consent.\n\nExclusion Criteria:\n\n* Acute respiratory failure or clinical instability.\n* Severe cognitive impairment or psychiatric disorders preventing reliable communication.\n* Active malignancy or terminal illness with a short life expectancy.\n* Refusal to provide informed consent.",{"count":120,"type":19},120,"This study aims to evaluate the psychometric properties, including reliability and validity, of the Turkish version of the Severe Respiratory Insufficiency Questionnaire for Non-Invasive Ventilation (S3-NIV). The S3-NIV is a specific tool designed to assess difficulties and compliance in patients receiving home non-invasive ventilation. A total of 120 stable patients using home NIV for at least 3 months will be enrolled across multiple centers.",[60,24],[124,125,126,127,128],"Non-Invasive Ventilation","Validation","Questionnaire","Reliability","S3-NIV","NOT_YET_RECRUITING","2026-05-27",{"date":132,"type":32},"2026-05-28",{"date":134,"type":19},"2026-05-21",{"date":136,"type":19},"2026-12-30",{"name":138,"class":39},"Istanbul Saglik Bilimleri University",{"id":140,"slug":141,"hasResults":11,"nctId":142,"briefTitle":143,"officialTitle":143,"acronym":4,"eligibilityCriteria":144,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":4,"enrollmentInfo":145,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":147,"conditions":148,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":40},"100625904","from-bench-to-bedside-a-machine-learning-tool-for-the-detection-of-inspiratory-leak-100625904","NCT07428694","From Bench to Bedside: A Machine Learning Tool for the Detection of Inspiratory Leak","Inclusion Criteria:\n\n* elective hospitalisation for control of non-invasive ventilation\n* use of ResMedLumis 100\u002F150 ventilator\n* treatment for \\>3 months\n\nExclusion Criteria:\n\n* current exacerbation",{"count":146,"type":19},20,"Study of the applicability of machine learning tools in detecting inspiratory leakage in longterm non-invasive ventilation. The study was conducted in two stages. Firstly the ML model was trained on both bench model created scenarios and then ten patients. And secondly the success of the model was assessed in a proof of concept pilot study of ten patients.",[24],"2026-02-17",{"date":151,"type":32},"2026-02-24",{"date":153,"type":32},"2025-10-01",{"date":155,"type":19},"2026-10-01",{"name":157,"class":39},"University of Oslo",{"id":159,"slug":160,"hasResults":11,"nctId":161,"briefTitle":162,"officialTitle":162,"acronym":163,"eligibilityCriteria":164,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":165,"enrollmentInfo":166,"targetDuration":4,"studyType":52,"phases":167,"briefSummary":168,"conditions":169,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":179,"locationsCount":40},"100538137","initiation-of-noninvasive-ventilation-in-als-patients-with-chronic-respiratory-insufficiency-100538137","NCT06286917","Initiation of Noninvasive Ventilation in ALS Patients With Chronic Respiratory Insufficiency","InNIVALS","Inclusion Criteria:\n\n* ALS diagnosed by a neurology and\n* chronic respiratory insufficiency or significant respiratory muscle weakness caused by ALS\n\nExclusion Criteria:\n\n* impaired cognition to give informed consent to participation\n* contraindication to NIV therapy\n* another severe disease with a prognosis of less than one year\n* ventilation via an artificial airway, tracheostomy","99 Years",{"count":120,"type":19},[90],"This research will study whether noninvasive ventilation (NIV) used to treat chronic respiratory insufficiency in patients with amyotrophic lateral sclerosis (ALS) can be initiated as successfully in the outpatient setting as in the conventional inpatient setting, and what the costs of these alternative initiation methods are.",[170,171,24],"Ventilation Therapy","ALS","2026-01-23",{"date":174,"type":32},"2026-01-27",{"date":176,"type":32},"2024-03-05",{"date":178,"type":19},"2029-12",{"name":180,"class":39},"Tampere University",{"id":182,"slug":183,"hasResults":11,"nctId":184,"briefTitle":185,"officialTitle":186,"acronym":4,"eligibilityCriteria":187,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":4,"enrollmentInfo":188,"targetDuration":4,"studyType":52,"phases":189,"briefSummary":190,"conditions":191,"keywords":193,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":198,"lastUpdatePostDateStruct":199,"startDateStruct":201,"completionDateStruct":203,"leadSponsor":204,"locationsCount":207},"100589315","validation-study-of-the-emily-ai-device-in-acute-and-chronic-respiratory-failure-100589315","NCT06952816","Validation Study of the EMILY AI Device in Acute and Chronic Respiratory Failure","Functional, Clinical, and Predictive Validation Study of the EMILY AI Device in Patients With Acute and Chronic Respiratory Failure","Inclusion Criteria:\n\n* Men and women over 18 years of age.\n* Admitted to intermediate respiratory care unit with a diagnosis of acute respiratory failure for at least 8 hours.\n* Informed consent understood and signed.\n\nExclusion Criteria:\n\n* Hemodynamic instability.\n* Severe temperature changes.\n* Hemoglobinopathies, severe anemia, severe acidosis, or severe alkalosis.\n* Anatomical disturbances.\n* Pregnancy or breastfeeding.",{"count":146,"type":19},[90],"Currently, there is no holistic solution for patients with respiratory diseases that includes oxygenation and management of a patient with respiratory disease, combining dynamic and automatic O2 administration and the detection of clinical worsening, generating a diagnostic suspicion, a management proposal, and notifying the medical team.\n\nFor device validation, prospective studies will be conducted in patients in respiratory intermediate care units, conventional hospitalization, during physical activity in the hospital setting, and in an out-of-hospital setting. The device will be evaluated in terms of oxygenation efficacy, response time, patient safety, efficiency, versatility, clinical benefit, and adaptability.",[24,192],"Acute Respiratory Failure",[194,195,196,197],"Respiratory failure","Hypoxia","Hyperxia","Oxigenotherapy","2026-01-08",{"date":200,"type":32},"2026-01-09",{"date":202,"type":32},"2025-04-23",{"date":136,"type":19},{"name":205,"class":206},"Aether Tech S.L.","INDUSTRY",2,{"id":209,"slug":210,"hasResults":11,"nctId":211,"briefTitle":212,"officialTitle":213,"acronym":214,"eligibilityCriteria":215,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":216,"enrollmentInfo":217,"targetDuration":4,"studyType":52,"phases":219,"briefSummary":220,"conditions":221,"keywords":4,"overallStatus":129,"whyStopped":4,"lastUpdateSubmitDate":224,"lastUpdatePostDateStruct":225,"startDateStruct":227,"completionDateStruct":228,"leadSponsor":230,"locationsCount":4},"100605067","advanced-respiratory-monitoring-and-oxygen-therapy-in-chronically-ill-patients-with-acute-respiratory-failure-100605067","NCT07157696","Advanced Respiratory Monitoring and Oxygen Therapy in Chronically Ill Patients With Acute Respiratory Failure","Advanced Bedside Lung Imaging and Respiratory Muscle Monitoring for Respiratory Support Management in Chronically Ill Patients With Acute Respiratory Failure: From Hospital to Home","HOME- Oxygen","Inclusion Criteria: Adults (≥18 years) with chronic respiratory (e.g., COPD, interstitial lung disease) and\u002For cardiac disease (e.g., heart failure), Clinical indication for long-term oxygen therapy, Capability to manage home-based devices independently or with caregiver assistance Signed informed consent\n\nExclusion Criteria:\n\nLife expectancy \\\u003C 3 months Inability to comply with home follow-up procedures.","80 Years",{"count":218,"type":19},16,[90],"This study is testing whether a new type of home oxygen therapy, called high-flow nasal cannula (HFNC), can improve breathing comfort and quality of life for people with long-term lung or heart conditions who need oxygen after leaving the hospital.\n\nHFNC delivers warm, humidified oxygen at higher flow rates than standard oxygen therapy, which may reduce shortness of breath, improve sleep, and make daily activities easier. The therapy will be provided using the myAirvo™3 device, which also allows doctors to check patients' oxygen levels, heart rate, and symptoms remotely. All patients will also wear a small device (RootiREX) to monitor heart rhythm, sleep quality, and detect breathing pauses at night.\n\nParticipants will try both treatments - HFNC and standard oxygen therapy - for short periods, in random order, so that researchers can directly compare the effects within the same patient. Each treatment period will last two weeks, with a short break in between.\n\nThe main goal of the study is to see whether HFNC reduces shortness of breath (measured by the modified Medical Research Council scale). Other outcomes include comfort, sleep quality, quality of life, oxygen levels, and how well patients are able to use the devices at home.\n\nThe study will last six weeks in total for each participant. Researchers expect that HFNC will improve breathing comfort, stabilize oxygen levels, and reduce the need for hospital visits during this time.",[24,222,223],"Cardiac Disease, Pulmonary Disease","Acute Respiratory Failure (ARF)","2025-10-02",{"date":226,"type":32},"2025-10-03",{"date":226,"type":19},{"date":229,"type":19},"2027-01-30",{"name":231,"class":39},"Università degli Studi di Ferrara",{"id":233,"slug":234,"hasResults":11,"nctId":235,"briefTitle":236,"officialTitle":237,"acronym":238,"eligibilityCriteria":239,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":4,"enrollmentInfo":240,"targetDuration":4,"studyType":52,"phases":242,"briefSummary":243,"conditions":244,"keywords":246,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":252,"lastUpdatePostDateStruct":253,"startDateStruct":255,"completionDateStruct":257,"leadSponsor":259,"locationsCount":40},"100543585","closed-loop-synchronization-versus-conventional-synchronization-in-spontaneously-breathing-adult-nonivasive-ventilationpatients-100543585","NCT06357780","Closed-loop syncHronization vErsuS convenTional Synchronization in sPontaneously Breathing Adult Nonivasive ventilationPatients","Closed-loop syncHronization vErsuS convenTional Synchronization in sPontaneously Breathing Adult Nonivasive Ventilation Patients (CHEST-SPAN) - a Randomized Cross-over Trial","CHESTSPAN","Inclusion Criteria:\n\n* Adult patients older than 18 years of age\n* Hospitalized at the ICU or emergency department with the intention of treatment with Noninvasive ventilation at least for the upcoming 2 hours with spontaneous breathing activity\n* Written informed consent signed and dated by the patient or one relative in case that the patient is unable to consent, after full explanation of the study by the investigator and prior to study participation\n\nExclusion Criteria:\n\n* Formalized ethical decision to withhold or withdraw life support\n* Patient included in another interventional research study under consent\n* Patient already enrolled in the present study in a previous episode of respiratory failure\n* Pregnant woman\n* Patients deemed at high risk for the need of transportation from an intensive care unit or emergency department to another ward, diagnostic unit or any other hospital\n* Hemodynamic instability defined as a need of continuous infusion of epinephrine or norepinephrine \\> 1 mg\u002Fh\n* Not being able to obtain reference waveforms due to technical or medical problems\n* Vulnerable population\n* Increase or decrease of ventilatory support either in pressures, fraction of inspired oxygen or mode of ventilation during study period",{"count":241,"type":19},38,[90],"The study is a multicentric prospective randomised cross-over study. It evaluates the compatibility of patients with the device without altering the routine treatment applied. During this evaluation, either the clinician-adjusted values on the device or the standard pre-set values are used to obtain hourly and 30-minute PVA (Patient Ventilator Asynchrony) recordings. These recordings will be analysed offline to identify the settings used and to compare the hourly and 30-minute PVA (Patient Ventilator Asynchrony) values when synchronisation is automatically set. The relationships and differences between these values will be analysed. For this purpose, the IntelliSync+ option, already available on the device, will be used. This software continuously analyses waveform signals at least a hundred times per second. This allows for the immediate detection of patient efforts and the initiation of inspiration and expiration in real time, thereby replacing traditional trigger settings for inspiration and expiration. If the patient is already synchronised with this option, it will then be possible to switch to traditional synchronisation settings for comparison. Statistical analyses will be conducted using SPSS 24.0, JASP (Just Another Statistical Programme), Jamovi ( fork of JASP), or R software. Initially, all numerical and categorical data will be evaluated using descriptive statistical methods. The distributions of numerical variables will be examined using visual (histograms and probability plots) and analytical methods (Kolmogorov-Smirnov\u002FShapiro-Wilk tests). Mean\u002FSD (standard deviation) or median\u002Finterquartile range (IQR) will be used as measures of distribution. For comparing numerical data that follows a normal distribution, the Student-t test will be used, and for non-normally distributed data, the Mann-Whitney U or Wilcoxon signed-rank tests will be employed. PVA (Patient Ventilator Asynchrony) values will be statistically compared. For the analysis of categorical data, the Chi-Square test will be applied. Bayesian analysis may also be used as necessary during the writing of the study. The results obtained will be interpreted and reported by the researchers. Results with a \"p\" value below 0.05 will be considered statistically significant.",[192,245,24],"Acute Respiratory Distress Syndrome",[247,248,249,250,251],"Acute respiratory failure (ARF)","noninvasive ventilation","Closed-loop","synchronization","patient ventilator asynchrony","2025-03-21",{"date":254,"type":32},"2025-03-26",{"date":256,"type":32},"2024-04-08",{"date":258,"type":19},"2025-12-31",{"name":260,"class":261},"Başakşehir Çam & Sakura City Hospital","OTHER_GOV"]